NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=134053&from=4 CLASS PERIOD ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/intellia-therapeutics- ...

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=132973&from=4 CLASS PERIOD ...

Core Insights - Intellia Therapeutics reported Q4 earnings, focusing on advancements in three Phase 3 trials for hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR) [1] Group 1: Company Progress - The company remains pre-revenue, indicating that it has not yet generated income from its operations [1] - The report highlighted significant progress in clinical trials, which is crucial for future revenue generation [1] Group 2: Leadership and Background - The company has a leadership team with strong academic and industry backgrounds, including experience at major pharmaceutical companies and biotech startups [1]

Intellia Therapeutics (NTLA) incurred a fourth-quarter 2024 loss of $1.24 per share (excluding one-time expenses of change in fair value of investments), which was narrower than the Zacks Consensus Estimate of a loss of $1.32. In the year-ago quarter, Intellia had incurred a loss of $1.46 per share. Including one-time expenses, the company reported a loss of $1.27 per share in the fourth quarter of 2024.See the Zacks Earnings Calendar to stay ahead of market-making news.The company’s total revenues currentl ...

NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/intellia-therapeutics- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-4785571 (State or other jurisdiction of incorp ...

Financial Data and Key Metrics Changes - As of December 31, 2024, the company's cash, cash equivalents, and marketable securities were approximately $861.7 million, down from $1 billion as of December 31, 2023 [31] - Collaboration revenue for Q4 2024 was $12.9 million, a significant increase from negative $1.9 million in Q4 2023, primarily driven by the Regeneron license and collaboration agreement [31] - R&D expenses increased to $116.9 million in Q4 2024 from $109 million in Q4 2023, reflecting advancements in lead programs [32] - G&A expenses rose to $32.4 million in Q4 2024 from $29 million in the prior year quarter, mainly due to stock-based compensation [32] Business Line Data and Key Metrics Changes - The company is focused on late-stage programs, particularly NTLA-2002 for hereditary angioedema (HAE) and nex-z for transthyretin amyloidosis (ATTR), with significant enrollment progress expected [8][12] - Enrollment in the Phase III study for NTLA-2002 is anticipated to be completed in 2026, while the MAGNITUDE study for ATTR is expected to exceed 550 patients by year-end 2025 [11][20] Market Data and Key Metrics Changes - The company sees substantial market opportunities in HAE and ATTR, with a focus on preparing for commercial phases as enrollment progresses [9][12] - The FDA granted nex-z Regenerative Medicine Advanced Therapy Designation (RMAT), facilitating closer collaboration as the company approaches a BLA filing in 2028 [26] Company Strategy and Development Direction - The company has prioritized resources on late-stage programs, discontinuing NTLA-3001 in favor of a second-generation approach [12] - The strategy includes building a commercial infrastructure in the U.S. for NTLA-2002, with plans for a successful launch between 2027 and 2030 [13][110] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational execution and the potential for near-term value creation through ongoing clinical programs [7][13] - The company anticipates a decline in GAAP operating expenses of approximately 5% to 10% year-over-year due to restructuring efforts [34] Other Important Information - The company welcomed Birgit Schultes as the new Chief Scientific Officer, bringing over 20 years of experience in drug development [14] - The company plans to present longer-term data from both ATTR-CM and ATTRv-PN patients later this year [27] Q&A Session Summary Question: Update on OpEx decline and trajectory - Management indicated that operating expenses were up 7% year-over-year, but restructuring efforts are expected to lead to a decline in OpEx over the next few years [42][48] Question: Phase III events accrual rate for nex-z - Management noted that enrollment is ahead of projections and expects favorable findings at the interim analysis [60] Question: Competition from Alnylam's next-generation TTR silencer - Management acknowledged the competitive landscape but emphasized the unique advantages of their approach and data [66][70] Question: Confidence in patient enrollment numbers for ATTR cardiomyopathy trial - Management expressed high confidence in reaching the enrollment target of 550 patients by year-end [79] Question: Commercial approach for HAE - Management highlighted the straightforward treatment regimen and the potential for a functional cure as key drivers for patient interest and reimbursement [86][88] Question: Long-term follow-up for HAE patients - Management indicated that all patients have shown improvement, and longer follow-up data will be reported later this year [95][97] Question: Preparations for BLA filing - Management confirmed that they are on track for a BLA filing in 2026, with favorable interactions with the FDA [106] Question: Sales force size for NTLA-2002 launch - Management did not disclose specific sales force size but indicated confidence in operationalizing the market opportunity [109] Question: Long-term observation data for HAE - Management plans to submit a supplemental BLA soon after initial approval, based on ongoing patient follow-up [117]

Financial Data and Key Metrics Changes - As of December 31, 2024, the company's cash, cash equivalents, and marketable securities were approximately $861.7 million, down from $1 billion as of December 31, 2023 [31] - Collaboration revenue for Q4 2024 was $12.9 million, a significant increase from negative $1.9 million in Q4 2023, driven mainly by the Regeneron license and collaboration agreement [31] - R&D expenses increased to $116.9 million in Q4 2024 from $109 million in Q4 2023, primarily due to advancements in lead programs [32] - G&A expenses rose to $32.4 million in Q4 2024 from $29 million in the prior year quarter, with stock-based compensation contributing to the increase [32] Business Line Data and Key Metrics Changes - The company is focused on late-stage programs, particularly NTLA-2002 for hereditary angioedema (HAE) and nex-z for transthyretin amyloidosis (ATTR), with significant enrollment progress expected [8][12] - Enrollment in the Phase III study for HAE (HAELO) is anticipated to be completed in the second half of 2025, while the MAGNITUDE study for ATTR is expected to exceed 550 patients by year-end [8][20] Market Data and Key Metrics Changes - The company sees substantial market opportunities in HAE and ATTR, with a focus on preparing for commercial phases as enrollment progresses [9][12] - The FDA granted nex-z Regenerative Medicine Advanced Therapy Designation (RMAT), facilitating closer collaboration as the company approaches a BLA filing in 2028 [26] Company Strategy and Development Direction - The company has prioritized resources on late-stage programs, discontinuing NTLA-3001 in favor of a second-generation approach [12] - The strategy includes building a commercial infrastructure in the U.S. for NTLA-2002, with plans for a successful launch in 2027 [30][110] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of operating expenses, expecting a decline of approximately 5% to 10% year-over-year due to restructuring efforts [34][48] - The company anticipates that peak operating expenses are behind them, with a steady state expected by 2026 as enrollment in studies completes [48] Other Important Information - The company welcomed Birgit Schultes as the new Chief Scientific Officer, bringing over 20 years of experience in drug development [14] - Management highlighted the importance of achieving a functional cure for patients with HAE, which is a key driver for market interest [155] Q&A Session Summary Question: Update on OpEx decline and restructuring - Management indicated that operating expenses were up 7% year-over-year, but restructuring efforts are expected to lead to a decline in future expenses [42][48] Question: Phase III events accrual rate for nex-z - Management noted that enrollment is ahead of projections and expects favorable findings at the interim analysis [60] Question: Competition from Alnylam's next-generation TTR silencer - Management acknowledged the competitive landscape but emphasized their unique approach and data supporting their therapy's efficacy [66][70] Question: Confidence in enrolling 550 patients for ATTR cardiomyopathy trial - Management expressed high confidence in achieving the enrollment target by year-end, citing robust enrollment rates [79] Question: Commercial approach for HAE - Management discussed the straightforward treatment regimen and ongoing efforts to ensure favorable reimbursement environments [85][89] Question: Long-term follow-up for HAE patients - Management indicated that all patients have shown improvement, and they expect to report on longer-term data later this year [96][97] Question: Preparations for BLA filing - Management confirmed that they are on track for a BLA filing in 2026, with favorable interactions with the FDA [106] Question: Sales force size for NTLA-2002 launch - Management refrained from specifying the sales force size but expressed confidence in operationalizing the market opportunity [110] Question: Long-term observation data for HAE - Management indicated that they will follow patients closely and expect to submit a supplemental BLA soon after initial approval [117]

Core Insights - Intellia Therapeutics reported better-than-expected fourth-quarter results, driven by increased collaboration revenue [1][7] Financial Performance - The company reported a net loss of $1.27 per share, which was better than the analysts' expectation of a $1.34 loss, and revenue of $12.9 million, significantly exceeding the $7 million estimate [1][2] - R&D expenses rose to $116.9 million, a 7.3% increase from $109 million in Q4 2023 [2][8] - For the full year, collaboration revenue reached $57.9 million, up from $36.3 million in 2023 [7] Company Overview and Strategy - Intellia utilizes CRISPR/Cas9 technology to develop gene-editing treatments for genetic diseases, focusing on lead programs NTLA-2001 and NTLA-2002 [3] - The company has prioritized late-stage programs and plans to reduce its workforce by about 27% in 2025 to align resources with core priorities [4] Clinical Developments - In Q4, Intellia initiated dosing in its global Phase 3 HAELO study for NTLA-2002, aiming for a 2027 U.S. market launch [5] - The MAGNITUDE Phase 3 trial for NTLA-2001 showed promising results with a 90% mean serum TTR reduction [6] Outlook - As of December 31, Intellia had a cash position of $861.7 million, projected to sustain operations through the first half of 2027 [9]